John Ducker | Association for Accessible Medicines
THANK YOU - for all those who made our first-ever #GRxBiosims virtual conference a success.

John Ducker

Board Initiative Sponsor: Predictable, Efficient Regulatory Systems
President and Chief Executive Officer, Fresenius Kabi USA, LLC
John Ducker
John Ducker
Fresenius Kabi USA, LLC

John Ducker is President and Chief Executive Officer of Fresenius Kabi USA, and a member of the Managing Board of its parent company, Fresenius Kabi AG. He is responsible for the company’s strategy and commercial operations in the United States and Canada.

John joined Fresenius Kabi in 1989 and became a member of the board of Fresenius Kabi AG in 2006 and has been in his current role since 2010.

During the course of his career John has had responsibility for global R&D, which included strategic portfolio management, medical and clinical affairs and regulatory affairs. He also led Fresenius Kabi businesses across several European countries and in other regions.

​John holds a bachelor’s and a master’s degree in Chemical Engineering from University of Cambridge in England.

Latest Tweets

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.